Literature DB >> 17425655

BY55/CD160 cannot be considered a cytotoxic marker in cytomegalovirus-specific human CD8(+) T cells.

J Merino1, N Ramírez, C Moreno, E Toledo, M Fernández, A Sánchez-Ibarrola.   

Abstract

CD160/BY55 is a glucosyl-phosphatidylinositol (GPI)-anchored cell membrane receptor that is expressed primarily in natural killer (NK) cells. Its presence in CD8(+) T lymphocytes is considered to be a marker of cytotoxic activity, although there are few data in this regard. In the present work, we analysed the expression of CD160 in subpopulations of cytomegalovirus (CMV)-specific CD8(+) T cells. Subpopulations were defined by CD28 and CD57 expression and exhibited varying degrees of differentiation and cytotoxic potential, as evaluated by the expression of perforin, interferon (IFN)-gamma and interleukin (IL)-7Ralpha/CD127. We included subjects with different intensities of anti-viral immune response. Results showed that the terminally differentiated CD28(-) CD57(+) subset displaying the highest level of perforin expressed CD160 at a level similar to that of memory CD28(+) CD57(-)perforin(-) cells. A comparison of the expression of perforin in CD160(+) cells versus CD160(-) cells showed that expression was significantly higher in the absence of CD160. Interestingly, the CMV-specific CD8(+) T cell subset from a patient with ongoing CMV reactivation did not begin to express CD160 until day +92 of the follow-up period. Taken together, our data show that CD160 cannot be considered a cytotoxic marker in CMV-specific CD8(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17425655      PMCID: PMC1942017          DOI: 10.1111/j.1365-2249.2007.03387.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

Review 1.  CD8+ T cell effector mechanisms in resistance to infection.

Authors:  J T Harty; A R Tvinnereim; D W White
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  Oligoclonal expansions in the CD8(+)CD28(-) T cells largely explain the shorter telomeres detected in this subset: analysis by flow FISH.

Authors:  F M Batliwalla; N Rufer; P M Lansdorp; P K Gregersen
Journal:  Hum Immunol       Date:  2000-10       Impact factor: 2.850

Review 3.  Biology of T memory type 1 cells.

Authors:  N Anfossi; V Pascal; E Vivier; S Ugolini
Journal:  Immunol Rev       Date:  2001-06       Impact factor: 12.988

4.  The increase of IFN-gamma production through aging correlates with the expanded CD8(+high)CD28(-)CD57(+) subpopulation.

Authors:  E Bandrés; J Merino; B Vázquez; S Inogés; C Moreno; M L Subirá; A Sánchez-Ibarrola
Journal:  Clin Immunol       Date:  2000-09       Impact factor: 3.969

5.  Beyond six colors: a new era in flow cytometry.

Authors:  Stephen C De Rosa; Jason M Brenchley; Mario Roederer
Journal:  Nat Med       Date:  2003-01       Impact factor: 53.440

6.  A soluble form of the MHC class I-specific CD160 receptor is released from human activated NK lymphocytes and inhibits cell-mediated cytotoxicity.

Authors:  Jérôme Giustiniani; Anne Marie-Cardine; Armand Bensussan
Journal:  J Immunol       Date:  2007-02-01       Impact factor: 5.422

7.  Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-) compartment.

Authors:  D M Sze; G Giesajtis; R D Brown; M Raitakari; J Gibson; J Ho; A G Baxter; B Fazekas de St Groth; A Basten; D E Joshua
Journal:  Blood       Date:  2001-11-01       Impact factor: 22.113

8.  BY55/CD160 acts as a co-receptor in TCR signal transduction of a human circulating cytotoxic effector T lymphocyte subset lacking CD28 expression.

Authors:  Maria Nikolova; Anne Marie-Cardine; Laurence Boumsell; Armand Bensussan
Journal:  Int Immunol       Date:  2002-05       Impact factor: 4.823

9.  Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants.

Authors:  Simon F Lacey; Ghislaine Gallez-Hawkins; Matthew Crooks; Joybelle Martinez; David Senitzer; Stephen J Forman; Ricardo Spielberger; John A Zaia; Don J Diamond
Journal:  Transplantation       Date:  2002-09-15       Impact factor: 4.939

10.  Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections.

Authors:  Victor Appay; P Rod Dunbar; Margaret Callan; Paul Klenerman; Geraldine M A Gillespie; Laura Papagno; Graham S Ogg; Abigail King; Franziska Lechner; Celsa A Spina; Susan Little; Diane V Havlir; Douglas D Richman; Norbert Gruener; Gerd Pape; Anele Waters; Philippa Easterbrook; Mariolina Salio; Vincenzo Cerundolo; Andrew J McMichael; Sarah L Rowland-Jones
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

View more
  5 in total

Review 1.  Positive and negative regulation of cellular immune responses in physiologic conditions and diseases.

Authors:  S Viganò; M Perreau; G Pantaleo; A Harari
Journal:  Clin Dev Immunol       Date:  2012-03-26

2.  Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than "Exhaustion" of Human CD8 T Cells.

Authors:  Amandine Legat; Daniel E Speiser; Hanspeter Pircher; Dietmar Zehn; Silvia A Fuertes Marraco
Journal:  Front Immunol       Date:  2013-12-19       Impact factor: 7.561

Review 3.  Inhibitory Receptors Beyond T Cell Exhaustion.

Authors:  Silvia A Fuertes Marraco; Natalie J Neubert; Grégory Verdeil; Daniel E Speiser
Journal:  Front Immunol       Date:  2015-06-26       Impact factor: 7.561

Review 4.  Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.

Authors:  Anna Śledzińska; Laurie Menger; Katharina Bergerhoff; Karl S Peggs; Sergio A Quezada
Journal:  Mol Oncol       Date:  2015-10-26       Impact factor: 6.603

5.  CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction.

Authors:  Yoav Peretz; Zhong He; Yu Shi; Bader Yassine-Diab; Jean-Philippe Goulet; Rebeka Bordi; Ali Filali-Mouhim; Jean-Baptiste Loubert; Mohamed El-Far; Franck P Dupuy; Mohamed Rachid Boulassel; Cécile Tremblay; Jean-Pierre Routy; Nicole Bernard; Robert Balderas; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  PLoS Pathog       Date:  2012-08-16       Impact factor: 6.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.